Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Cancer Immunology, Immunotherapy : CII
|
June 9, 2004
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
E Claire Dees, Karen P McKinnon, Jennifer J Kuhns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Annals of Surgical Oncology
|
October 14, 2021
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience
Michael J Carr, James Sun, Danielle DePalo, et al.
JCO Oncology Practice
|
July 9, 2021
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform
Richard L Martin, Michael J Grant, Stephen Kimani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Nature Medicine
|
August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Cancer Discovery
|
April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1
Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Cancer Immunology, Immunotherapy : CII
|
June 9, 2004
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
E Claire Dees, Karen P McKinnon, Jennifer J Kuhns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Annals of Surgical Oncology
|
October 14, 2021
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience
Michael J Carr, James Sun, Danielle DePalo, et al.
JCO Oncology Practice
|
July 9, 2021
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform
Richard L Martin, Michael J Grant, Stephen Kimani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Nature Medicine
|
August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Cancer Discovery
|
April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1
Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
Page
of 3